How has Geisinger reduced device costs in clinically sensitive areas? Attend a webinar, March 7
Skip to Content

Is your system utilizing Exparel appropriately?

US health systems spend $270M annually on Exparel, but has it shown superiority over older analgesics? This case study describes how one health system used clinical evidence to work with physicians to eliminate unnecessary Exparel utilization.

Read this article to: 

  • Learn how one organization saved nearly $1M off a base spend of $1.2M
  • See what the evidence says about Exparel’s relationship to improved outcomes
  • Discover how mapping your spend and utilization data to clinical evidence can drive change